Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 16/20 | 0.72 |
| ▸ | WNT3A | P56704 | 14/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979790 | 0.91 | CTNNB1 (0.72) | CTNNB1WNT3A | |
| SCHEMBL653271 | 0.84 | CTNNB1 (1.00) | CTNNB1WNT3ANPC1RAB9APKM | |
| SCHEMBL15979799 | 0.81 | CTNNB1 (0.77) | CTNNB1WNT3A | |
| SCHEMBL15979792 | 0.76 | CTNNB1 (0.80) | CTNNB1WNT3ANPC1RAB9APKM | |
| SCHEMBL14410546 | 0.74 | CTNNB1 (0.56) | CTNNB1WNT3ANPC1RAB9APKM | |
| SCHEMBL654355 | 0.74 | CTNNB1 (1.00) | CTNNB1WNT3APKM | |
| SCHEMBL15979791 | 0.74 | CTNNB1 (0.69) | CTNNB1WNT3APKM | |
| SCHEMBL15979793 | 0.73 | CTNNB1 (0.72) | CTNNB1WNT3A | |
| SCHEMBL15988825 | 0.73 | CTNNB1 (0.69) | CTNNB1WNT3ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15988776 | 0.73 | CTNNB1 (0.73) | CTNNB1WNT3ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303010-B2 | β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303010-B2 | β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150299174-A1 | B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2015-10-22 | — | — | US | disclosed |
| US-20150299174-A1 | B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299174-A1 | B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3B, GSK3A, WNT3A | CTNNB1 7/4885WNT3A 3/4885NPC1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.